289 related articles for article (PubMed ID: 24610826)
1. Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.
Haq R; Fisher DE; Widlund HR
Clin Cancer Res; 2014 May; 20(9):2257-63. PubMed ID: 24610826
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.
Haq R; Shoag J; Andreu-Perez P; Yokoyama S; Edelman H; Rowe GC; Frederick DT; Hurley AD; Nellore A; Kung AL; Wargo JA; Song JS; Fisher DE; Arany Z; Widlund HR
Cancer Cell; 2013 Mar; 23(3):302-15. PubMed ID: 23477830
[TBL] [Abstract][Full Text] [Related]
3. Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene.
Hall A; Meyle KD; Lange MK; Klima M; Sanderhoff M; Dahl C; Abildgaard C; Thorup K; Moghimi SM; Jensen PB; Bartek J; Guldberg P; Christensen C
Oncotarget; 2013 Apr; 4(4):584-99. PubMed ID: 23603840
[TBL] [Abstract][Full Text] [Related]
4. Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma.
Smith LK; Rao AD; McArthur GA
Pharmacol Res; 2016 May; 107():42-47. PubMed ID: 26924126
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial metabolism is inhibited by the HIF1α-MYC-PGC-1β axis in BRAF V600E thyroid cancer.
Gao Y; Yang F; Yang XA; Zhang L; Yu H; Cheng X; Xu S; Pan J; Wang K; Li P
FEBS J; 2019 Apr; 286(7):1420-1436. PubMed ID: 30768848
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
7. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
8. New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations.
Ferretta A; Maida I; Guida S; Azzariti A; Porcelli L; Tommasi S; Zanna P; Cocco T; Guida M; Guida G
Biochim Biophys Acta; 2016 Nov; 1863(11):2710-2718. PubMed ID: 27542908
[TBL] [Abstract][Full Text] [Related]
9. Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers.
Strohecker AM; White E
Cancer Discov; 2014 Jul; 4(7):766-72. PubMed ID: 24860158
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
11. CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism.
Cho H; Shen Q; Zhang LH; Okumura M; Kawakami A; Ambrose J; Sigoillot F; Miller HR; Gleim S; Cobos-Correa A; Wang Y; Piechon P; Roma G; Eggimann F; Moore C; Aspesi P; Mapa FA; Burks H; Ross NT; Krastel P; Hild M; Maimone TJ; Fisher DE; Nomura DK; Tallarico JA; Canham SM; Jenkins JL; Forrester WC
Cell Chem Biol; 2021 Oct; 28(10):1407-1419.e6. PubMed ID: 33794192
[TBL] [Abstract][Full Text] [Related]
12. Oxidative Phosphorylation as an Emerging Target in Cancer Therapy.
Ashton TM; McKenna WG; Kunz-Schughart LA; Higgins GS
Clin Cancer Res; 2018 Jun; 24(11):2482-2490. PubMed ID: 29420223
[TBL] [Abstract][Full Text] [Related]
13. Molecular drivers of cellular metabolic reprogramming in melanoma.
Abildgaard C; Guldberg P
Trends Mol Med; 2015 Mar; 21(3):164-71. PubMed ID: 25618774
[TBL] [Abstract][Full Text] [Related]
14. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
15. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
Preto A; Gonçalves J; Rebocho AP; Figueiredo J; Meireles AM; Rocha AS; Vasconcelos HM; Seca H; Seruca R; Soares P; Sobrinho-Simões M
BMC Cancer; 2009 Oct; 9():387. PubMed ID: 19878585
[TBL] [Abstract][Full Text] [Related]
16. HMG-CoA synthase 1 is a synthetic lethal partner of BRAF
Zhao L; Fan J; Xia S; Pan Y; Liu S; Qian G; Qian Z; Kang HB; Arbiser JL; Pollack BP; Kudchadkar RR; Lawson DH; Rossi M; Abdel-Wahab O; Merghoub T; Khoury HJ; Khuri FR; Boise LH; Lonial S; Chen F; Chen J; Lin R
J Biol Chem; 2017 Jun; 292(24):10142-10152. PubMed ID: 28468827
[TBL] [Abstract][Full Text] [Related]
17. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence.
Kaplon J; Zheng L; Meissl K; Chaneton B; Selivanov VA; Mackay G; van der Burg SH; Verdegaal EM; Cascante M; Shlomi T; Gottlieb E; Peeper DS
Nature; 2013 Jun; 498(7452):109-12. PubMed ID: 23685455
[TBL] [Abstract][Full Text] [Related]
18. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R
Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684
[TBL] [Abstract][Full Text] [Related]
19. In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.
Guo X; Xu Y; Zhao Z
Mol Cancer; 2015 Mar; 14():60. PubMed ID: 25890285
[TBL] [Abstract][Full Text] [Related]
20.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
[Next] [New Search]